登录 | 注册    关注公众号  
微信公众号
搜索
 >  Protein>IL-15 >IL5-H4117

Human IL-15 Protein (E. coli), premium grade

GMP version GMP-L15H13 is now available for seamless transition.

分子别名(Synonym)

IL-15,Interleukin-15,MGC9721

表达区间及表达系统(Source)

Human IL-15, premium grade (IL5-H4117) is expressed from E. coli cells. It contains AA Asn 49 - Ser 162 (Accession # P40933-1).

Predicted N-terminus: Met

It is produced under our rigorous quality control system that incorporates a comprehensive set of tests including sterility and endotoxin tests. Product performance is carefully validated and tested for compatibility for cell culture use or any other applications in the early preclinical stage.
GMP-L15H13 is the GMP version of this IL5-H4117. These two proteins display indistinguishable performance profiles, thereby ensuring a seamless transition for end users from early preclinical stag to later clinical phases.

Request for sequence

蛋白结构(Molecular Characterization)

IL-15 Structure

This protein carries no "tag".

The protein has a calculated MW of 12.9 kDa. The protein migrates as 13 kDa±3 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE).

内毒素(Endotoxin)

Less than 0.01 EU per μg by the LAL method.

宿主蛋白残留(Host Cell Protein)

<0.5 ng/µg of protein tested by ELISA.

宿主核酸残留(Host Cell DNA)

<0.02 ng/μg of protein tested by qPCR.

无菌(Sterility)

Negative

支原体(Mycoplasma)

Negative.

纯度(Purity)

>95% as determined by SDS-PAGE.

制剂(Formulation)

Lyophilized from 0.22 μm filtered solution in 25 mM Histidine, pH6.2 with trehalose as protectant.

Contact us for customized product form or formulation.

重构方法(Reconstitution)

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存储(Storage)

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

  1. -20°C to -70°C for 12 months in lyophilized state;
  2. -70°C for 3 months under sterile conditions after reconstitution.

质量管理控制体系(QMS)

  1. 质量管理体系(ISO, GMP)
  2. 质量优势
  3. 质控流程
 

电泳(SDS-PAGE)

IL-15 SDS-PAGE

Human IL-15, premium grade on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).

 

活性(Bioactivity)-CELL BASE

IL-15 CELL

Human IL-15, premium grade (Cat. No. IL5-H4117) stimulates proliferation of CTLL-2 cells. The specific activity of Human IL-15, premium grade is > 8.00ⅹ10^6 IU/mg, which is calibrated against human IL-15 WHO International Standard (NIBSC code: 95/554) (QC tested).

Protocol

IL-15 CELL

Human IL-15, premium grade (Cat. No. IL5-H4117), designed for preclinical stage, has the same activity and performance with GMP Human IL-15 (Cat. No. GMP-L15H13), which enables a seamless transition from preclinical development to clinical phases.

Protocol

 

活性(Bioactivity)-ELISA

IL-15 ELISA

Immobilized Human IL-15, premium grade (Cat. No. IL5-H4117) at 2 μg/mL (100 μL/well) can bind Human IL-15 R alpha, Fc Tag (Cat. No. ILA-H5253) with a linear range of 0.6-39 ng/mL (Routinely tested).

Protocol

 

活性(Bioactivity)-SPR

IL-15 SPR

Human IL-2 R beta, Fc Tag (Cat. No. ILB-H5253) captured on CM5 chip via anti-human IgG Fc antibody, can bind Human IL-15, premium grade (Cat. No. IL5-H4117) with an affinity constant of 9.5 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

Protocol

 

活性(Bioactivity)-BLI

IL-15 BLI

Loaded Human IL-2 R beta, Fc Tag (Cat. No. ILB-H5253) on Protein A Biosensor, can bind Human IL-15, premium grade (Cat. No. IL5-H4117) with an affinity constant of 10.2 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Protocol

 

稳定性(Stability)

IL-15 STABILITY

The Cell based assay shows batch-to-batch consistency between Acro's GMP and PG IL-15.

 
评论(3)
  1. 医疗检测
  2. 3人赞
  3. 这个价格还是挺划算的,感觉这个不比GMP级别的差多少,可能是我们没有那么高的要求吧,不过作为国产的确实已经很不错了,主要是质量稳定,货期快,比较适合我们科研的
  4. 2022-11-18
  1. 130XXXXXXX1
  2. 2人赞
  3. 人重组白介素15细胞因子是我们常用的细胞体外培养所需的生物试剂,主要用于细胞活化扩增,所以这款高质量的细胞因子对细胞培养功不可没
  4. >
  5. 2022-8-3
  1. 158XXXXXXX8
  2. 0人赞
  3. 多次购买acro的蛋白了!Acro公司产品包装很好、发货速度快,满满的干冰,保证了运输途中的低温度,防止蛋白降解。蛋白纯度高,用来做体外功能试验和亲和力检测,功能验证结果很好!多次合作伙伴!!超赞!!相比于其他厂家性价比高,值得信赖!!强烈推荐!!
  4. 2023-5-2
 
ACRO质量管理体系
 
 

背景(Background)

Interleukin 15 is also known as IL15, IL-15, and is a cytokine with structural similarity to IL-2. Like IL-2, IL-15 binds to and signals through the IL-2/IL-15 beta chain (CD122) and the common gamma chain (gamma-C, CD132). IL-15 is secreted by mononuclear phagocytes (and some other cells) following infection by virus(es). This cytokine induces cell proliferation of natural killer cells; cells of the innate immune system whose principal role is to kill virally infected cells. Interleukin 15 (IL-15) regulates T and natural killer (NK) cell activation and proliferation. Survival signals that maintain memory T cells in the absence of antigen are provided by IL-15. This cytokine is also implicated in NK cell development. In rodent lymphocytes, IL-15 prevents apoptosis by inducing an apoptosis inhibitor, BCL2L1/BCL-x(L). IL-15 has been shown to enhance the anti-tumor immunity of CD8+ T cells in pre-clinical models. A phase I clinical trial to evaluate the safety, dosing, and anti-tumor efficacy of IL-15 in patients with metastatic melanoma and renal cell carcinoma (kidney cancer) has begun to enroll patients at the National Institutes of Health.

 

前沿进展

Nociceptor neurons promote PDAC progression and cancer pain by interaction with cancer-associated fibroblasts and suppression of natural killer cells
Wang, Ni, Xie et al
Cell Res (2025)
Abstract: The emerging field of cancer neuroscience has demonstrated great progress in revealing the crucial role of the nervous system in cancer initiation and progression. Pancreatic ductal adenocarcinoma (PDAC) is characterized by perineural invasion and modulated by autonomic (sympathetic and parasympathetic) and sensory innervations. Here, we further demonstrated that within the tumor microenvironment of PDAC, nociceptor neurons interacted with cancer-associated fibroblasts (CAFs) through calcitonin gene-related peptide (CGRP) and nerve growth factor (NGF). This interaction led to the inhibition of interleukin-15 expression in CAFs, suppressing the infiltration and cytotoxic function of natural killer (NK) cells and thereby promoting PDAC progression and cancer pain. In PDAC patients, nociceptive innervation of tumor tissue is negatively correlated with the infiltration of NK cells while positively correlated with pain intensity. This association serves as an independent prognostic factor for both overall survival and relapse-free survival for PDAC patients. Our findings highlight the crucial regulation of NK cells by nociceptor neurons through interaction with CAFs in the development of PDAC. We also propose that targeting nociceptor neurons or CGRP signaling may offer a promising therapy for PDAC and cancer pain.© 2025. The Author(s) under exclusive licence to Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences.
Enhancing human NK cell antitumor function by knocking out SMAD4 to counteract TGFβ and activin A suppression
Rea, Santana-Hernández, Villanueva et al
Nat Immunol (2025)
Abstract: Transforming growth factor beta (TGFβ) and activin A suppress natural killer (NK) cell function and proliferation, limiting the efficacy of adoptive NK cell therapies. Inspired by the partial resistance to TGFβ of NK cells with SMAD4 haploinsufficiency, we used CRISPR-Cas9 for knockout of SMAD4 in human NK cells. Here we show that SMAD4KO NK cells were resistant to TGFβ and activin A inhibition, retaining their cytotoxicity, cytokine secretion and interleukin-2/interleukin-15-driven proliferation. They showed enhanced tumor penetration and tumor growth control, both as monotherapy and in combination with tumor-targeted therapeutic antibodies. Notably, SMAD4KO NK cells outperformed control NK cells treated with a TGFβ inhibitor, underscoring the benefit of maintaining SMAD4-independent TGFβ signaling. SMAD4KO conferred TGFβ resistance across diverse NK cell platforms, including CD19-CAR NK cells, stem cell-derived NK cells and ADAPT-NK cells. These findings position SMAD4 knockout as a versatile and compelling strategy to enhance NK cell antitumor activity, providing a new avenue for improving NK cell-based cancer immunotherapies.© 2025. The Author(s).
An intraepithelial ILC1-like natural killer cell subset produces IL-13
Maddineni, Sharma, Mohammad et al
Front Immunol (2025) 16, 1521086
Abstract: Natural killer (NK) cells are innate immune effectors with considerable heterogeneity and potent antitumor capabilities. Intraepithelial ILC1 (ieILC1)-like NK cells, a population of cytotoxic tissue-resident innate lymphoid cells, have recently been documented in the microenvironment of head and neck squamous cell carcinomas (HNSCC) and other solid tumors. These cells have antitumor cytolytic potential and are potent producers of type 1 cytokines, including IFNγ. Here, we identify a subpopulation of ex vivo differentiated ieILC1-like NK cells that produce IL-13 upon stimulation. Functional characterization revealed that these cells co-expressed IFNγ and IL-13 while maintaining an ILC1 transcriptional signature. IL-13 was induced either upon co-culture with tumor cell lines, or in response to TGF-β and IL-15. IL-13-expressing ieILC1-like NK cells were identified among tumor infiltrating lymphocytes expanded from patient HNSCC tumors, in support of their in vivoexistence in primary tumors. These data demonstrate additional heterogeneity within the ieILC1-like NK cell population than previously appreciated and highlight a unique form of ILC plasticity in which cells with clear ILC1 transcriptional profiles express a type 2 cytokine. With the known roles of IL-13 in cancer cell growth dynamics and immunoregulation, the identification of this subset within tumor microenvironments presents a potential target for therapeutic manipulation.Copyright © 2025 Maddineni, Sharma, Mohammad, Ruggiero-Sherman, Stepanek, Shin, Bando and Sunwoo.
Plasma Cytokine and Chemokine Profiles Predict Efficacy and Toxicity of Anti-CD19 CAR-T Cell Therapy in Large B-Cell Lymphoma
Zeng, Zhang, Wang et al
Clin Lymphoma Myeloma Leuk (2025)
Abstract: Anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy has emerged as a promising treatment for large B-cell lymphoma (LBCL); however, durable complete responses are achieved in only 30% to 40% of patients. Additionally, CAR-T therapy is frequently associated with significant toxicities, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).We explored the translational potential of cytokines and chemokines as predictive biomarkers for CAR-T outcomes by analyzing 47 plasma cytokines/chemokines in serial blood samples from 24 LBCL patients undergoing CAR-T therapy. Blood samples were collected at multiple times: prelymphodepletion, day of CAR-T infusion (Day 0), and post-infusion. We investigated the association between cytokine levels and key clinical outcomes using machine learning models, including treatment response at 3 months, CRS, and ICANS.Higher day 0 IL-7, day 7 IL-21, and day 0 CCL8 levels correlated with improved remission rates. Conversely, elevated CRS risk was linked to higher day 0 CCL17 and day 3 CCL13, IL-6, and IFN-γ levels. ICANS development was associated with increased day 0 TGF-β1, and day 3 IL-5 and IL-7 levels, while lower day 0 CCL19 and day 3 VIP levels were inversely related to ICANS risk. Additionally, patients who received higher-intensity lymphodepletion had elevated day 0 CCL2 and IL-15 levels.These findings highlight the role of plasma cytokines and chemokines as biomarkers for predicting both the therapeutic efficacy and toxicity of CART, with the potential to guide more personalized, safer, and effective immunotherapies for B cell lymphoma.Copyright © 2025. Published by Elsevier Inc.
Showing 1-4 of 8137 papers.
Powered by BizGenius
 
 
货号/价格
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
IL-15靶点信息
英文全称:Interleukin-15
中文全称:白细胞介素-15
种类:Homo sapiens
上市药物数量:0详情
临床药物数量:19详情
最高研发阶段:临床二期
查看更多信息
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定